Approved for use through 07/51/2012 OM9 06/51-0031

U.S. Patent and Trademark Office, U.S. DEFARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless at contains a valid OMS control number.

Complete if Known Substitute for form 1449/PTO Application Number 10/589,825-Conf. #2356 INFORMATION DISCLOSURE Filing Date December 15, 2006 STATEMENT BY APPLICANT Paul BOULANGE First Named Inventor Art Unit 1656 (Use as many sheets as necessary) Examiner Name A. U. Desai Sheet of 1 Attorney Docket Number 0040-0165PUS1

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No.1	Document Number Number-Kind Code ² (If known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	AA*	US-20030232969	12-18-2003	Lengsfeld et al.	
	AB*	US-5,346,992			

FOREIGN PATENT DOCUMENTS						
Examiner initials*	Cite No.1	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages Or Relevant Figures Appear	
		Country Code ³ -Number ⁴ -Kind Code ⁵ (# Innown)				T ⁶
	ВА	EP-0 498 133-A1	08-12-1992	Pasteur Merieux Serums Vacc		П
	BB	EP-1 329 461-A1	07-23-2003	Juridical Foundation		\Box
	BC	EP-1614424-A1	01-11-2006	Juridical Foundation		
	BD	WO-9600237-A1	01-04-1996	Pharmacia Ab et al.		
L		l		L		Ш

and the second s	
Examiner	Date
Signature	in the second se
Signature	Considered

"EXAMINER: Intitle I reterence considered, whether or not clatifion is in continuance with MFEP 000. Draw like through citation if not in continuance and not considered. Include copy of leb from with end communication logistics." (CTER No. 10 Times application), which are marked with an incipil sateristic (Tom to the Clark No. 10 to the Clark N

Examiner Initials	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, bournal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T2
	CA	BURNOUF, T. et al., "Reducing the risk of infection from plasma products: specific preventative strategies", Blood Reviews, 2000, Vol. 14, pp. 94-110.	
	СВ	Internet Excerpt - product specification of PLANOVA filters of ASAHI KASEI MEDICAL.	Г
	СС	KASPER, Carol K. et al., Registry of Clotting Factor Concentrates, fifth Edition, 2004, WORLD FEDERATION OF HEMOPHILIA, Montreal, CANADA.	Г
	CD	MORGENTHALER, Jean-Jacques, "Securing viral safety for plasma derivatives", Transfusion Medicine Reviews, Vol. 15, No. 3, July 2001, pp. 224-233.	
	CE	Tarelli, Edward et al., "Recombinant human albumin as a stabilizer for biological materials and for the preparation of international reference reagents", Biologicals (1998), Vol. 26, pp. 331-346.	
	CF	TATEISHI, Jun et al., "Scrapie removal using Planova® virus removal filters", Biologicals, 2001, Vol. 29, pp. 17-25.	
	CG	ROEMMP CHEMIE LEXIKON, 9th edition, published by Georg Thieme Verlag Stuttgart, New York, volume 3, page 2034.	

Examiner Signature	/Anand Desai/	Date Considered	12/20/2010

"EXAMINER: initial it reterence considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered, include copy of this form with next communication to applicant. "Applicant is unjue citation designation number (options)." Applicant is to place a check mark here it English language Translation is attached.